

Pharmaderm Co SAE

BALANCE SHEET
AS AT Mar 31, 2023
Amount in Local Currency

ASSETS	Notes	As at 31.03.2023		As at 31.03.2022	
ASSETS					
1. Non-Current Assets					
(a) Property, Plant and Equipment	3.1	2,316,550		2,408,843	
(b) Capital Work-in-Progress	3.1	-		-	
(c) Investment Property	3.2	-		-	
(d) Goodwill on Consolidation	3.3				
(e) Right of Use Assets					
(f) Intangible Assets	3.3	-		-	
(g) Intangible Assets under Development	3.3	-		-	
(h) Financial Assets					
(i) Investments	3.4	-		-	
(ii) Loans	3.5	-		-	
(iii) Others	3.6	-		-	
(i) Other Non-Current Assets	3.7	256,512	2,573,062	256,512	2,665,355
2. Current Assets					
(a) Inventories	3.8	-		-	
(b) Financial Assets					
(i) Investments	3.4	-		-	
(ii) Trade Receivables	3.9	-		-	
(iii) Cash and Cash Equivalents	3.10	283,251		777,630	
(iv) Bank Balance other than (iii) above	3.11	1,052,132		1,015,429	
(v) Loans	3.12	-		-	
(vi) Other Financial Assets	3.13	-		-	
(c) Current Tax Assets (Net)	3.14	-		-	
(d) Other Current Assets	3.15	938,693	2,274,076	938,693	2,731,752
Total Assets			4,847,138		5,397,107
EQUITY AND LIABILITIES					
EQUITY					
(a) Equity Share Capital	3.16	2,126,000		2,126,000	
(b) Other Equity	3.17	(55,793,557)	(53,667,557)	(31,571,608)	(29,445,608)
1. Non-Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings	3.18	58,338,848		34,520,062	
(ii) Other Financial Liabilities	3.19	-		-	
(b) Provisions	3.20	-		-	
(c) Deferred Tax Liabilities (Net)	3.21	-		-	
(d) Other Non-Current Liabilities	3.22	-	58,338,848	-	34,520,062
2. Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings	3.23	-		-	
(ii) Trade Payables	3.24				
Total outstanding dues of Micro, Small & Medium Enterprises (MSME)		-		-	
Total outstanding dues of creditors Other than MSME		175,762		322,569	
(iii) Other Financial Liabilities	3.25	-		-	
(b) Other Current Liabilities	3.26	84		84	
(c) Provisions	3.27	-		-	
(d) Current Tax Liabilities (Net)					
			175,846		322,653
Total Equity and Liabilities			4,847,138		5,397,107

Amitabh Goika

Amitabh Goika
Director
Date-12-May-23



Pharmaderm Co SAE

STATEMENT OF PROFIT AND LOSS ACCOUNT

Particulars		Twelve Month Mar'23	Twelve Month Mar'22
Income			
Revenue from Operations		-	-
Other Income		36,702	36,702
Total Income	(A)	36,702	36,702
Expenses			
Cost of Materials Consumed		-	-
Purchases of Stock-in-Trade		-	-
(Increase)/Decrease in Inventories of Finished Goods, Stock in Trade and Work-in-Progress		-	-
Excise duty on sale of Goods		69,470	73,575
Employee Benefits Expense		24,096,888	4,971,182
Other Expenses			
Total Expenses Before Interest, Depreciation, Amortisation and Tax	(B)	24,166,358	5,044,757
Earning Before Interest, Depreciation, Amortisation and Tax	(A-B)	(24,129,656)	(5,008,055)
Finance Costs	(C)	-	-
Depreciation, Amortisation & Impairment Expense:			
a) Amortisation & Impairment of Intangible Assets		-	-
b. Depreciation on Right of use assets		-	-
c) Depreciation of Tangible Assets		92,293	92,293
Total Expenses	(B+C+D)=E	24,258,651	5,137,050
Profit Before tax and exceptional items	(A-E)=F	(24,221,949)	(5,100,348)
Exceptional items	(G)		
Profit Before tax	(F-G)=H	(24,221,949)	(5,100,348)
Tax Expense:	(I)		
Current Tax (MAT)			
Provision of Earlier Years			
MAT Credit Entitlement			
Deferred Tax charge			
Profit for the year	(H-I)=J	(24,221,949)	(5,100,348)
Other Comprehensive Income			
Items that will not be reclassified to Profit or Loss in subsequent periods			
Equity Instrument through Other Comprehensive Income (net of tax)			
Remeasurement of the net defined benefit liability/ asset (net of tax)			
Income Tax Effect			
Total Other Comprehensive Income, net of tax		-	-
Total Comprehensive Income for the year		(24,221,949)	(5,100,348)

Amitabh Goeka
Amitabh Goeka
Director
Date-12-May-23



Pharmaderm Co SAE

Notes to Financial statements
3.1 Property Plant & Equipment(Current Year)

Particulars	Gross Block			Depreciation			Net Block		
	As at 1.4.2022	Additions	Disposals/ Transfer	As at 31.03.2023	As at 1.4.2022	For the Period	Disposals/ Transfer	As at 31.03.2023	As at 31.3.2022
Land <i>Leasehold</i> <i>Freehold</i>	1,216,431	-	-	1,216,431	-	-	-	1,216,431	-
Building (including roads)*	2,052,044	-	-	2,052,044	918,240	62,989	-	1,070,815	1,133,804
Plant & Equipment	291,045	-	-	291,045	286,261	2,392	-	2,392	4,784
Furniture & Fixture	250,175	-	-	250,175	196,400	26,888	-	26,887	53,775
Office Equipment	-	-	-	-	-	-	-	-	-
Computer	2,714	-	-	2,714	2,665	24	-	25	49
Motor Vehicles	-	-	-	-	-	-	-	-	-
Property, Plant & Equipment Total	3,812,409	-	-	3,812,409	1,403,566	92,293	-	2,316,550	2,408,843
Capital Work- In-Progress	-	-	-	-	-	-	-	-	-
Total	3,812,409	-	-	3,812,409	1,403,566	92,293	-	2,316,550	2,408,843

Attach G-1-



Pharmaderm Co SAE
Notes to Financial Statements

3.7 Other Non-current Assets

	As at 31.03.2023	As at 31.03.2022
Unsecured, Considered Good unless otherwise stated		
Capital Advances		
Deposit with Government authorities	256,512	256,512
Prepaid Expenses		
Advance income tax (Net of Provision)		
Incentives Receivables		
Less: Provision for Doubtful Receivables		
Total	256,512	256,512

3.10 Cash and Cash Equivalents

	As at 31.03.2023	As at 31.03.2022
Cash and Cash Equivalents		
Balances with Banks	282,101	776,480
Fixed Deposits with Banks (Original Maturity of less than 3 Months)		
Cash on hand	1,150	1,150
Cheques in hand		
Total	283,251	777,630

3.11 Other Bank Balances

	As at 31.03.2023	As at 31.03.2022
At amortised cost		
Other Bank Balances		
Unpaid Dividend account		
Deposit with Original maturity of more than 3 months but less than 12 months	1,052,132	1,015,429
Total	1,052,132	1,015,429

3.15 Other Current Assets

	As at 31.03.2023	As at 31.03.2022
Unsecured, considered good		
Advances other than Capital Advances		
For goods and services	490,332	490,332
To employees		
Balances with Excise and Sales Tax Department	448,350	448,350
Prepaid Expenses	11	11
Total	938,693	938,693

3.16 Equity Share Capital

	As at 31.03.2023	As at 31.03.2022
Authorised		
Issued	2,126,000	2,126,000
Subscribed & Paid up*	2,126,000	2,126,000
Total Issued, Subscribed and Fully paid up Share Capital	2,126,000	2,126,000

Annex C-1



3.17 Other Equity

	As at 31.03.2023	As at 31.03.2022
Retained Earnings		
Opening balance	(34,437,355)	(29,337,007)
Net Profit for the Year	(24,221,949)	(5,100,348)
Remeasurements of the Net Defined Benefit Plans (net of tax)		
IND AS 115 Impact		
Income Tax Effect		
Final Dividend#		
Corporate Dividend Tax#		
Closing Balance	(58,659,304)	(34,437,355)
Other Comprehensive Income		
Opening Balance	2,865,747	2,865,747
Equity Instruments through Other Comprehensive Income		
Income Tax Effect		
Closing Balance	2,865,747	2,865,747
Other Reserves		
Total	(55,793,557)	(31,571,608)

3.18 Borrowings

	As at 31.03.2023	As at 31.03.2022
At amortised cost		
Unsecured		
Loan from related party		
(Emami Overseas FZE -Holding Company)	58,338,848	34,520,062
		-
Total	58,338,848	34,520,062

3.24 Trade Payables

	As at 31.03.2023	As at 31.03.2022
At amortised cost		
Total outstanding dues of Micro, Small & Medium Enterprises (MSME)		
Total outstanding dues of creditors Other than MSME	175,762	322,569
Total	As at 31.03.2023	322,569

3.26 Other Current Liabilities

	As at 31.03.2023	As at 31.03.2022
Deferred government grant		
Refund Liabilities		
Advance from Customers		
Duties & Taxes	84	84
Total	84	84

Antal G-1



Pharmaderm Co SAE
Notes to Financial Statements

3.29 Other Income

	Twelve Month Mar'23	Twelve Month Mar'22
Interest Received on financial assets carried at amortised cost		
Loans & Deposits		
Others	36,702	36,702
Dividend Income from equity investment carried at cost		
Dividend Income from equity investment carried at fair value through OCI		
Income received on investment carried at fair value through Profit or Loss		
Dividend from investment in mutual funds		
Profit/ (loss) on Sale of mutual funds		
Profit/ (loss) on Derivative instruments		
Profit/ (loss) on Sales of Property, Plant & Equipments		
Rent and Maintenance Charges Received		
Sundry Balances Written Back		
Miscellaneous Receipts		
Net foreign exchange gain	-	
Total	36,702	36,702

3.32 Employee Benefit Expenses

	Twelve Month Mar'23	Twelve Month Mar'22
Salaries and Wages	69,470	73,575
Staff Contribution to Provident and Other Funds		
Gratuity Expenses		
Welfare Expense		
Total	69,470	73,575

3.34 Other Expenses

	Twelve Month Mar'23	Twelve Month Mar'22
Consumption of Stores and Spare parts		
Power and Fuel	13,981	11,526
Rent		
Repairs & Maintenance :		
Building		
Machinery		
Others		
Insurance		
Rates and Taxes	-	-
Freight & Forwarding		
Directors' Fees and Commission		
Advertisement & Sales Promotion		
Packing Charges		
Commission		
Loss on Sale/Disposal of Property, Plant & Equipments		
Bank charges	310	-
Legal and Professional Fees	254,106	72,116
Travelling and Conveyance	5,565	5,675
Expenditure on CSR Activities		
Miscellaneous Expenses	4,140	4,305
Net foreign exchange loss	23818786	4,877,560
Total	24,096,888	4,971,182

Depreciation, Amortisation & Impairment Expense

	Twelve Month Mar'23	Twelve Month Mar'22
a. Amortisation & Impairment of Intangible Assets	-	-
c. Depreciation of Other Assets	92,293	92,293
Total	92,293	92,293

Anto L G.



Reporting Company Name	Related Party Name	Nature of Relationship	Transaction Details	Item Type	For PL Items Twelve Month Mar'23	For BS Items As at 31.03.2023
Pharmaderm Company SAE	Emami Overseas FZE	Parent Company	Loan Payable	PL/BS BS		58,338,848

Attach G-1-

